Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Joe E. who wrote (3115)	12/3/1997 6:11:00 PM
From: Izzy	of 6136

Joe E.: Thank you for the excellent FDA url on PIs, which I think all should read carefully. A few comments: 1) Viracept should have been included as a PI demonstrating "reductions in both mortality and AIDS-defining clinical events" (I have asked AGPH to respond); 2) clearly Viracept has the most favorable adverse effect (side-effects) profile; 3) patients should not take Versed (commonly used sedative for diagnostic procedures, such as bronchoscopy/colonoscopy); Viracept appears to have the best profile for not having other drug interactions, esp the NNRTIs; 4) patients should be careful with oral contraceptives. Personally, I cannot medically justify prescribing any other PI except Viracept.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next